Publications by authors named "Rick Roos"
Many physicians and patients hold the (unconscious) belief that intravenous antibiotic therapy is superior to oral therapy. This belief is also reflected in guidelines, where increasing severity of infection often leads to the recommendation of intravenous options only. But is this belief justified, and where does it come from? Treating with oral antibiotics has many potential advantages, such as fewer hospital admissions and the prevention of related complications.
View Article and Find Full Text PDFArticle Synopsis
- Community-acquired Pneumonia (CAP) guidelines usually recommend admitting patients with moderate-to-severe cases and treating them with intravenous antibiotics.
- A study at Haga Teaching Hospital compared outcomes of patients with moderate-to-severe CAP treated with oral antibiotics versus those treated with intravenous antibiotics, using a cohort of 314 patients.
- Results showed no significant differences in 30-day mortality, ICU admission, or readmission rates, but intravenous patients had a longer hospital stay by an average of 2.6 days, suggesting oral antibiotics could be a safe alternative for selected patients.
Tailored anticoagulant treatment after a first venous thromboembolism: protocol of the Leiden Thrombosis Recurrence Risk Prevention (L-TRRiP) study - cohort-based randomised controlled trial.
BMJ Open
March 2024
Introduction: Patients with a first venous thromboembolism (VTE) are at risk of recurrence. Recurrent VTE (rVTE) can be prevented by extended anticoagulant therapy, but this comes at the cost of an increased risk of bleeding. It is still uncertain whether patients with an intermediate recurrence risk or with a high recurrence and high bleeding risk will benefit from extended anticoagulant treatment, and whether a strategy where anticoagulant duration is tailored on the predicted risks of rVTE and bleeding can improve outcomes.
View Article and Find Full Text PDFArticle Synopsis
- Older adults with moderate-to-severe lower respiratory tract infections often face hospitalization, leading to potential negative outcomes like delirium and functional decline due to factors like poor coordination in regional care and financial barriers.
- This study will evaluate a new care pathway called 'The Hague RTI Care Bridge' that aims to treat these patients outside of a hospital setting, assessing its feasibility, safety, patient satisfaction, and overall health outcomes.
- The study involves participants aged 65 and older and will compare their experiences in an outpatient care pathway against those treated in a hospital, with results published in international peer-reviewed journals.
Unlabelled: The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) earlier this year recommended to suspend some marketing authorisations for Gadolinium Containing Contrast Agents (GCCAs) based on linear chelators due to the potential risk of gadolinium retention in the human body. These recommendations have recently been re-evaluated by EMA's Committee for Medicinal Products for Human Use (CHMP), and confirmed the final opinion of the European Medicines Agency. This editorial provides an overview of the available GCCAs and summarises the recent evidence of gadolinium retention.
View Article and Find Full Text PDF